The new oral anti-coagulants and the phase 3 clinical trials - a systematic review of the literature

Thrombosis Journal

Volumn 11, Issue 1, 2013, Pages

  Tahir, Faryal ^a   Riaz, Haris ^a   Riaz, Talha ^a   Badshah, Maaz B ^b   Riaz, Irbaz B ^c   Hamza, Ameer ^d   Mohiuddin, Hafsa ^a  

^a DOW UNIVERSITY OF HEALTH SCIENCES   (Pakistan)

^b INDIANA UNIVERSITY   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d QUAID E AZAM MEDICAL COLLEGE   (Pakistan)

Author keywords

Acute coronary syndrome; Apixaban; Atrial fibrillation; Critically ill patients; Dabigatran; Hip replacement; Knee replacement; Oral anticoagulants; Orthopedic surgery; Rivaroxaban; Systematic review; Venous thromboembolism; Vitamin K antagonists

Indexed keywords

ACETYLSALICYLIC ACID; APIXABAN; ATECEGATRAN METOXIL; ATORVASTATIN; BETRIXABAN; CLOPIDOGREL; CYTOCHROME P450 3A4; DABIGATRAN; DALTEPARIN; DAREXABAN; DICLOFENAC; DIGOXIN; EDOXABAN; ENOXAPARIN; LETAXABAN; MULTIDRUG RESISTANCE PROTEIN; PLACEBO; RIVAROXABAN; SOFIGATRAN; TECARFARIN; WARFARIN;

ACUTE CORONARY SYNDROME; ANTICOAGULATION; BLEEDING; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; CRITICALLY ILL PATIENT; DEEP VEIN THROMBOSIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; HEART ATRIUM FIBRILLATION; HEART DEATH; HEART INFARCTION; HIP ARTHROPLASTY; HUMAN; INFORMATION RETRIEVAL; KNEE ARTHROPLASTY; LUNG EMBOLISM; MEDLINE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; ORTHOPEDIC SURGERY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; RESPIRATORY FAILURE; REVIEW; RISK ASSESSMENT; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SYSTEMATIC REVIEW; THROMBOEMBOLISM; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM;

EID: 84883267213     PISSN: None     EISSN: 14779560     Source Type: Journal    
DOI: 10.1186/1477-9560-11-18     Document Type: Review

References (52)

1. Eikelboom JW, Weitz JI. New anticoagulants. Circulation 2010, 121(13):1523-1532. 10.1161/CIRCULATIONAHA.109.853119, 20368532.
2. Altman R, Vidal HO. Battle of oral anticoagulants in the field of atrial fibrillation scrutinized from a clinical practice (the real world) perspective. Thromb J 2011, 9:12. 3161913, 21794130.
3. Raghavan N, Frost CE, Yu Z, He K, Zhang H, Humphreys WG, Pinto D, Chen S, Bonacorsi S, Wong PC, Zhang D. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 2009, 37(1):74-81. 10.1124/dmd.108.023143, 18832478.
4. Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development. Clin Pharmacokinet 2009, 48(1):1-22. 10.2165/0003088-200948010-00001, 19071881.
5. Buller H, Deitchman D, Prins M, Segers A. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. J Thromb Haemost 2008, 6(8):1313-1318.
6. Lassen MR, Davidson BL, Gallus A, Pineo G, Ansell J, Deitchman D. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost 2007, 5(12):2368-2375. 10.1111/j.1538-7836.2007.02764.x, 17868430.
7. Ogawa S, Shinohara Y, Kanmuri K. Safety and efficacy of the oral direct factor xa inhibitor apixaban in Japanese patients with non-valvular atrial fibrillation. -The ARISTOTLE-J study-. Circ J 2011, 75(8):1852-1859. 10.1253/circj.CJ-10-1183, 21670542.
8. Goldhaber SZ, Leizorovicz A, Kakkar AK, Haas SK, Merli G, Knabb RM, Weitz JI. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med 2011, 365(23):2167-2177. 10.1056/NEJMoa1110899, 22077144.
9. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 2009, 361(6):594-604. 10.1056/NEJMoa0810773, 19657123.
10. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010, 375(9717):807-815. 10.1016/S0140-6736(09)62125-5, 20206776.
11. Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 2010, 363(26):2487-2498. 10.1056/NEJMoa1006885, 21175312.
12. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011, 365(11):981-992. 10.1056/NEJMoa1107039, 21870978.
13. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, Flaker G, Avezum A, Hohnloser SH, Diaz R, Talajic M, Zhu J, Pais P, Budaj A, Parkhomenko A, Jansky P, Commerford P, Tan RS, Sim KH, Lewis BS, Van Mieghem W, Lip GY, Kim JH, Lanas-Zanetti F, Gonzalez-Hermosillo A, Dans AL, Munawar M, O'Donnell M, Lawrence J, Lewis G, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011, 364(9):806-817. 10.1056/NEJMoa1007432, 21309657.
14. Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P, Bhatt DL, Goodman S, Verheugt FW, Flather M, Huber K, Liaw D, Husted SE, Lopez-Sendon J, De Caterina R, Jansky P, Darius H, Vinereanu D, Cornel JH, Cools F, Atar D, Leiva-Pons JL, Keltai M, Ogawa H, Pais P, Parkhomenko A, Ruzyllo W, Diaz R, White H, Ruda M, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011, 365(8):699-708. 10.1056/NEJMoa1105819, 21780946.
15. Kubitza D, Becka M, Roth A, Mueck W. Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. Curr Med Res Opin 2008, 24(10):2757-2765. 10.1185/03007990802361499, 18715524.
16. Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 2005, 78(4):412-421. 10.1016/j.clpt.2005.06.011, 16198660.
17. Kubitza D, Mueck W, Becka M. Randomized, double-blind, crossover study to investigate the effect of rivaroxaban on QT-interval prolongation. Drug Saf 2008, 31(1):67-77. 10.2165/00002018-200831010-00006, 18095747.
18. Cohen AT, Spiro TE, Büller HR, Haskell L, Hu D, Hull R, Mebazaa A, Merli G, Schellong S, Spyropoulos AC, Tapson V, MAGELLAN Investigators Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med 2013, 368(6):513-523. 10.1056/NEJMoa1111096, 23388003, MAGELLAN Investigators.
19. Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F, Geerts W. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008, 358(26):2765-2775. 10.1056/NEJMoa0800374, 18579811.
20. Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, Soglian AG, Pap AF, Misselwitz F, Haas S. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008, 372(9632):31-39. 10.1016/S0140-6736(08)60880-6, 18582928.
21. Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, Misselwitz F, Turpie AG. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008, 358(26):2776-2786. 10.1056/NEJMoa076016, 18579812.
22. Turpie AG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM, Cushner FD, Lotke PA, Berkowitz SD, Bandel TJ, Benson A, Misselwitz F, Fisher WD. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009, 373(9676):1673-1680. 10.1016/S0140-6736(09)60734-0, 19411100.
23. Fox KA, Piccini JP, Wojdyla D, Becker RC, Halperin JL, Nessel CC, Paolini JF, Hankey GJ, Mahaffey KW, Patel MR, Singer DE, Califf RM. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011, 32(19):2387-2394. 10.1093/eurheartj/ehr342, 21873708.
24. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011, 365(10):883-891. 10.1056/NEJMoa1009638, 21830957.
25. Mega JL, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F, Hricak V, Barnathan ES, Bordes P, Witkowski A, Markov V, Oppenheimer L, Gibson CM. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 2009, 374(9683):29-38. 10.1016/S0140-6736(09)60738-8, 19539361.
26. Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, Burton P, Cohen M, Cook-Bruns N, Fox KA, Goto S, Murphy SA, Plotnikov AN, Schneider D, Sun X, Verheugt FW, Gibson CM. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012, 366(1):9-19. 10.1056/NEJMoa1112277, 22077192.
27. Buller HR, Lensing AW, Prins MH, Agnelli G, Cohen A, Gallus AS, Misselwitz F, Raskob G, Schellong S, Segers A. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. Blood 2008, 112(6):2242-2247. 10.1182/blood-2008-05-160143, 18621928.
28. Agnelli G, Gallus A, Goldhaber SZ, Haas S, Huisman MV, Hull RD, Kakkar AK, Misselwitz F, Schellong S. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study. Circulation 2007, 116(2):180-187. 10.1161/CIRCULATIONAHA.106.668020, 17576867.
29. Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010, 363(26):2499-2510.
30. Büller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SD, Bounameaux H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012, 366(14):1287-1297.
31. Chung N, Jeon HK, Lien LM, Lai WT, Tse HF, Chung WS, Lee TH, Chen SA. Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non-valvular atrial fibrillation. Thromb Haemost 2011, 105(3):535-544.
32. Mendell J, Tachibana M, Shi M, Kunitada S. Effects of food on the pharmacokinetics of edoxaban, an oral direct factor Xa inhibitor, in healthy volunteers. J Clin Pharmacol 2011, 51(5):687-694. 10.1177/0091270010370974, 20534818.
33. Raskob G, Cohen AT, Eriksson BI, Puskas D, Shi M, Bocanegra T, Weitz JI. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study. Thromb Haemost 2010, 104(3):642-649. 10.1160/TH10-02-0142, 20589317.
34. Fuji T, Fujita S, Tachibana S, Kawai Y. A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty. J Thromb Haemost 2010, 8(11):2458-2468. 10.1111/j.1538-7836.2010.04021.x, 20723033.
35. Weitz JI, Connolly SJ, Patel I, Salazar D, Rohatagi S, Mendell J, Kastrissios H, Jin J, Kunitada S. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost 2010, 104(3):633-641. 10.1160/TH10-01-0066, 20694273.
36. Ruff CT, Giugliano RP, Antman EM, Crugnale SE, Bocanegra T, Mercuri M, Hanyok J, Patel I, Shi M, Salazar D, McCabe CH, Braunwald E. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J 2010, 160(4):635-641. 10.1016/j.ahj.2010.06.042, 20934556.
37. Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 2008, 36(2):386-399. 10.1124/dmd.107.019083, 18006647.
38. Stangier J, Rathgen K, Stähle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate. Clin Pharmacokinet 2010, 49(4):259-268. 10.2165/11318170-000000000-00000, 20214409.
39. European Medicines Agency Summary of Product Characteristics: Pradaxa (dabigatran etexilate). European Medicines Agency 2011, Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf [Accessed September 5, 2013], European Medicines Agency.
40. Stangier J, Rathgen K, Stähle H, Reseski K, Körnicke T, Roth W. Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics. Am J Cardiovasc Drugs 2009, 9(1):59-68. 10.1007/BF03256595, 19178132.
41. Stangier J, Stähle H, Rathgen K, Reseski K, Körnicke T. No interaction of the oral direct thrombin inhibitor dabigatran etexilate and digoxin [abstract]. J Thromb Haemost 2007, 5(S2):abstract P-W-672.
42. Stangier J, Stähle H, Rathgen K, Reseski K, Körnicke T. Coadministration of the oral direct thrombin inhibitor dabigatran etexilate and diclofenac has little impact on the pharmacokinetics of either drug [abstract]. J Thromb Haemost 2007, 5(S2):abstract P-T-677.
43. Stangier J, Clemens A. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost 2009, 15(Suppl 1):9S-16S.
44. Stangier J, Eriksson BI, Dahl OE, Ahnfelt L, Nehmiz G, Stähle H, Rathgen K, Svärd R. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol 2005, 45(5):555-563. 10.1177/0091270005274550, 15831779.
45. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Prins MH, Hettiarachchi R, Hantel S, Schnee J, Büller HR. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007, 370(9591):949-956. 10.1016/S0140-6736(07)61445-7, 17869635.
46. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Kälebo P, Christiansen AV, Hantel S, Hettiarachchi R, Schnee J, Büller HR. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007, 5(11):2178-2185. 10.1111/j.1538-7836.2007.02748.x, 17764540.
47. Eriksson BI, Dahl OE, Huo MH, Kurth AA, Hantel S, Hermansson K, Schnee JM, Friedman RJ. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial. Thromb Haemost 2011, 105(4):721-729. 10.1160/TH10-10-0679, 21225098.
48. Ginsberg JS, Davidson BL, Comp PC, Francis CW, Friedman RJ, Huo MH, Lieberman JR, Muntz JE, Raskob GE, Clements ML, Hantel S, Schnee JM, Caprini JA. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009, 24(1):1-9.
49. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009, 361(12):1139-1151. 10.1056/NEJMoa0905561, 19717844.
50. Oldgren J, Budaj A, Granger CB, Khder Y, Roberts J, Siegbahn A, Tijssen JG, Van de Werf F, Wallentin L. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J 2011, 32(22):2781-2789. 10.1093/eurheartj/ehr113, 21551462.
51. Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: metaanalysis of noninferiority randomized controlled trials. Arch Intern Med 2012, [Epub ahead of print].
52. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009, 361(24):2342-2352. 10.1056/NEJMoa0906598, 19966341.